Showing posts sorted by date for query LSD. Sort by relevance Show all posts
Showing posts sorted by date for query LSD. Sort by relevance Show all posts

Tuesday, November 19, 2024

STALINISM REDUX

Hong Kong court jails 45 democracy campaigners on subversion charges

By AFP
November 18, 2024

Police keep watch outside the West Kowloon Magistrates' Court in Hong Kong during the sentencing of the city's most prominent democracy campaigners - Copyright AFP Peter PARKS

A Hong Kong court on Tuesday jailed all 45 defendants convicted in the city’s largest trial under its sweeping national security law, with “mastermind” Benny Tai receiving the longest sentence of 10 years.

Tai’s jail term is the longest yet handed out under the law, which was imposed by Beijing in 2020 to quash dissent after massive, sometimes violent pro-democracy protests the year before.

The group, which included figures from across Hong Kong’s once-diverse political spectrum, was charged with subversion after they held an informal poll in 2020 as part of a strategy to win a pro-democracy electoral majority.

Along with Tai, pro-democracy politicians Au Nok-hin, Andrew Chiu, Ben Chung and Australian citizen Gordon Ng were singled out as organisers and received sentences of up to seven years and three months.

Australia’s government said it was “gravely concerned” by the sentencing.

The other forty received terms beginning from four years and two months.

After Tai, the second longest sentence was handed to young activist Owen Chow, at seven years and nine months, with the court saying he “took a more proactive role in the scheme than other defendants”.

“Long Hair” Leung Kwok-hung, the 68-year-old co-founder of the city’s last standing opposition party the League of Social Democrats, received a term of six years and nine months.

– ‘ Refused to be tamed’ –

His wife and LSD leader Chan Po-ying told AFP outside the courtroom that the term was “within our expectations”.

“It is what it is — no matter (whether) I laugh or I cry so I choose to laugh a bit,” she said.

Leticia Wong, a former district councillor for a since-disbanded pro-democracy party who attended the sentencing, told AFP that she found the terms were “encouraging people to plead guilty and testify against their peers”.

“For those who refused to be tamed, punishment is obviously heavier,” Wong said.

Western countries and international rights groups have condemned the trial as evidence of Hong Kong’s increased authoritarianism.

China and Hong Kong say the security law restored order following the 2019 protests, and have warned against “interference” from other countries.

Forty-seven people were initially charged after they were arrested in January 2021, making this case the largest by number of defendants.

Thirty-one pleaded guilty, and 16 stood a 118-day trial last year, with 14 convicted and two acquitted in May.

– ‘Constitutional crisis’ –


The aim of the election primary, which took place in July 2020, was to pick a cross-party shortlist of pro-democracy candidates to increase their electoral prospects.

If a majority was achieved, the plan was to force the government to meet the 2019 protesters’ demands — including universal suffrage — by threatening to indiscriminately veto the budget.

Three senior judges handpicked by the government to try security cases said the group would have caused a “constitutional crisis”.

Anna Kwok, executive director of the Washington-based Hong Kong Democracy Council, condemned the sentencing as “an attack on the essence of Hong Kong – one that yearns for freedom, democracy and the right to political expression”.
















Acquitted ‘Hong Kong 47’ defendant sees freedom as responsibility


By AFP
November 19, 2024

Pro-democracy activist Lee Yue-Shun, one of only two to walk away from the high-profile security case, attended the trial every day in carefully coordinated outfits -

 Copyright AFP ISAAC LAWRENCE

Xinqi SU

As the massive trial of the “Hong Kong 47” democracy campaigners ended on Tuesday, an acquitted member of the group watched from the sidelines and felt the weight of his freedom upon him.

Former district councillor and street dancer Lee Yue-shun is one of only two people to have walked away from a national security law trial.

On Tuesday, 45 of his co-defendants were handed prison terms of up to 10 years for subversion.

It is Hong Kong’s largest prosecution under its 2020 security law, imposed by Beijing after huge, sometimes violent pro-democracy protests the year before.

“I find the situation (of being acquitted) quite hard to understand,” Lee told AFP in a series of interviews ahead of the sentencing.

“I think (the acquittal) gave me more responsibility — how can I make better use of the freedom I have not lost,” the 31-year-old added.

On Tuesday, Lee arrived outside court at 4 am (2000 GMT) to try and get a public seat.

“I come here today mainly (out of) a duty to show my concern for this important court case as a citizen,” he told AFP.

“I also want more people to notice the development and the conclusion of the case.”



– ‘Intention to subvert’ –



The 47 were charged after holding an unofficial election primary in July 2020, in a bid to make a shortlist aimed at gaining a pro-democracy majority in the legislature.

If victorious, they planned to force the government to meet the 2019 protesters’ demands — including universal suffrage — by threatening vetoes of the city budget.

Judges ruled they would have created “a constitutional crisis”, and 45 were convicted of subversion.

But Lee and another defendant, veteran lawyer Lawrence Lau, were acquitted.

Judges said they could not be sure Lee “was a party to the Scheme” nor that he “had the intention to subvert”.

Until the duo’s release in May, national security cases prosecuted under the 2020 law had a 100 percent conviction rate.

While Hong Kong’s legislature has been purged of opposition and scores of civil society groups have shuttered since the law’s passage, authorities maintain it restored order and stability after months of unrest.

“We have lost a lot of freedoms… All I can say is that the acquittal means I lost one less,” Lee said.



– Social justice vision –



Lee jokingly referred to himself as “a loser” — he struggled at school and failed to get into university first time round.

“But Hong Kong gave me a vision,” he said, and he decided to pursue a career as a social worker.

He first dipped his toes into politics as a student, working as a campaign helper for a pro-democracy party.

Lee soon caught the party’s eye as a candidate to attract young voters, and ran for district council at the height of the 2019 protests.

He was put forward in the election primary almost at the last minute.

He lost, but at dawn on January 6, 2021, was woken up by banging on his door.

It was the national security police.

“I couldn’t make sense of it at that time. I asked if many people were arrested. They said yes,” Lee recalled.



– ‘Come what may’ –



Lee was luckier than the others — he was granted bail after two weeks, whereas most of the 47 have been detained since that day.

Even so, stringent bail conditions kept him “trapped” in Hong Kong for nearly 1,200 days.

His passport was seized, and he was banned from speaking publicly in any way deemed to endanger national security.

“Over these three years — which I would describe as a test — I had been emphasising this: I would not let my life be destroyed,” Lee said.

“Until the last moment before the ruling, I had been thinking: ‘Come what may, there are still things I want to carry on’.”

Lee threw himself into street dance and boxing, and appeared at every trial day in carefully coordinated outfits.

He also completed a law programme, with his final thesis analysing the conspiracy charge in common law — using his own case as an example.

Two weeks after his acquittal, Lee retrieved his passport from the court, and in early July, he renewed his social worker licence.

“I will now make more active and better use of this basic right (of movement) to further develop myself… to encourage more and different people here,” he said.

Written By AFP

With 2,400 staff representing 100 different nationalities, AFP covers the world as a leading global news agency. AFP provides fast, comprehensive and verified coverage of the issues affecting our daily lives.





Tuesday, November 12, 2024

Canada should be ‘world leader’ on alternative PTSD therapies, veteran says

By Sean Boynton Global News
Posted November 10, 2024

WATCH: After being injured in Canada's longest, most expensive war effort, one veteran created and fundraised an exhibit to help ensure the efforts of those who served — and the memories those who died — aren't forgotten. Mercedes Stephenson explains  


Canadian Forces veteran who served in Afghanistan says Canada should be a “world leader” on alternative therapies for treating veterans’ post-traumatic stress disorder and other post-combat trauma, including the use of psychedelics.

Retired MCpl. Gordon Hurley says psychedelic treatments such as ketamine and psilocybin, or “magic mushrooms,” can give veterans “a breath of relief” from their trauma or addictions, pointing to his own experience, and is calling for further study and coverage for physician-assisted therapies.

“I really think we’re in a unique position as a country, with such a liberal view on health care and life, that we should be able to be a world leader in providing alternative therapies,” he told Mercedes Stephenson in an interview that aired Sunday on The West Block ahead of Remembrance Day.

“We should be doing the same thing with our veterans just how you send us to war. A majority of the time we’re saying, ‘Send me, send me.’ We can do the same thing with these types of treatments.”

Hurley deployed to Afghanistan in the summer of 2008, just 15 months after joining the military and completing basic training. He was injured by an improvised explosive device but returned to the battlefield just three weeks after surgery.


2:21
Nova Scotia company to examine magic mushrooms as PTSD treatment



More than 40,000 Canadians served in Afghanistan, many on multiple tours during the 20-year global War on Terror, and 165 Canadian Armed Forces members died there.

Many veterans of that war returned to Canada suffering not just from PTSD but also traumatic brain injuries and effects from toxic burn pit exposure, among other traumas.

Research has suggested recent veterans have had a higher rate of mental health and addiction issues compared to older veterans and the overall Canadian population.

Veterans Affairs Canada is conducting research and clinical trials into the use of ketamine as a treatment for traumatic brain injuries and depression, but has yet to launch a similar project on psilocybin. Independent studies have been launched across Canada in recent years into psychedelic treatments

A Senate committee report last December urged the federal government to “immediately” conduct a “major research program” into how psychedelics can help veterans suffering from PTSD. The report said research already exists into the effectiveness of such treatments and warned Canada is falling behind other countries in studying them.

The United States has funded research into psychedelic treatments for veterans, but the U.S. FDA this year rejected an approval for MDMA treatment, calling for further study.

Briefing notes prepared for the veterans affairs minister last year say the department only provides financial coverage for treatments that are supported by solid research, and says approved psychological and psychiatric treatments are the “first-line evidence-based” approach to treating PTSD and other mental issues.

2:01
Psychedelics approved for medical use in Canada


“Western treatment is completely fine,” Hurley said. “There’s nothing wrong with prescription drugs or SSDIs (antidepressants), whatever is going to work to get that person off the ledge is worth it. But there are other treatment options.”

Hurley said he travels to Mexico to receive treatment through psychedelics through a clinic run by Canadian doctors, and touted their effectiveness.

Besides psychedelics, Hurley also pointed to a treatment known as stellate ganglion block, which numbs nerves in the neck and “basically resets your nervous system,” he said. The treatment has been studied at multiple Canadian hospitals and universities and has been called “miraculous” in treating PTSD.

“To get that initial breath and that initial pause where they don’t have the cravings for their addiction, or they don’t have the annoyances of trauma, of post-traumatic stress, of perhaps being too freaked out to go into public spaces or noises and all these other detriments to the veteran’s life … we could be fixing with different types of treatment,” he said.

Hurley said the government should particularly cover assisted treatment programs that allow doctors to work with patients and ensure veterans are taking the proper treatments and dosages.

“The doctor is going to have specific training to deal with psychedelics and how that integrates into a person’s life,” he said.

“We’re so new to it. It’s not anyone’s fault, but we should really be ahead of the curve on this.”

Psychedelic therapy provides hope for veterans

Story by Maya Goldman


Psychedelic therapy provides hope for veterans

Veterans are campaigning to take psychedelic therapy for post-traumatic stress disorder mainstream, despite the Food and Drug Administration's rejection of an ecstasy-based therapy in August.

Why it matters: About 29% of veterans who fought in Afghanistan and Iraq will have PTSD at some point in their lives, according to the Department of Veterans Affairs. Veteran suicide rates are also higher than in the general population.

"The thirst is very palpable among our generation" of veterans for alternative mental health therapies, Allison Jaslow, CEO of Iraq and Afghanistan Veterans of America, told Axios.

Catch up quick: Psychedelics like magic mushrooms, LSD and ecstasy can alter a person's state of mind and cause hallucinations.
It's been nearly impossible to research their effects, because they've been criminalized and classified as controlled substances since 1970.
But interest in psychedelics' potential to treat mental health conditions — particularly in veterans — has grown in recent years.
The FDA in 2017 granted fast-track review of a PTSD treatment that mixes ecstasy with talk therapy.

The VA started funding research into psychedelic therapies this year. Congress also passed bipartisan legislation directing the Pentagon to study the treatments.
In the meantime, more than 1,200 veterans traveled to other countries for psychedelic therapies through one nonprofit alone, said Jesse Gould, founder of that organization, Heroic Hearts Project.

But the FDA in August rejected the therapy it had originally fast-tracked, following an independent review that highlighted concerns like missing safety data and allegations of misconduct in clinical trials.

Zoom in: The decision felt like a major setback to veterans.
"It was emotionally just gut-wrenching, thinking about all of those veterans, and all the other people, for that matter, that were just really counting on being able to access this as a solution for their debilitating PTSD," said Juliana Mercer, a Marine Corps veteran and director at veterans advocacy group Healing Breakthrough.
The FDA rejection pushes mental health progress back years, added Gould, a former Army Ranger. It "indicates to veterans that they are not being listened to and they're not a priority."

Where it stands: Veterans are continuing to work toward broadening access to psychedelic therapies.
State-level action is also picking up. Oregon and Colorado have legalized psychedelic mushrooms for therapeutic use. But Massachusetts voters last week rejected a ballot proposal to legalize psychedelics.

What's next: The company behind the rejected ecstasy-based therapy now has a new acting CEO and chief medical officer, and it announced last month that it will run a new clinical trial on the PTSD treatment.

The VA has reportedly said it would consider funding the trial.
The FDA also fast-tracked review for a psychedelic mushroom therapy, though the company running that trial announced recently that it's delaying a key data release.

The new clinical trials will likely take at least two more years, Mercer predicted.
But the extended timeline means the VA "is going to be more prepared to effectively roll out a psychedelic program," she said. "I'm choosing to look at that as a silver lining."


Smoking toad venom helps veterans with PTSD, addiction, and depression

Allan Rose Hill
Mon Nov 11, 2024
BOING!BOING!


image: Deep Desert Photography/Shutterstock (manipulated)

Zach Skiles is a veteran and clinical psychologist who, informed by his own experiences, is helping other veterans deal with PTSD, depression, and drug addiction. As a researcher with University of California at San Francisco, Skiles leads veterans through psychedelic experiences to help alleviate some of their suffering. The participants are first given ibogaine—a natural stimulant with psychedelic properties found in the West African shrub iboga. After a long "group healing" session, they are administered 5-MeO-DMT, an extremely powerful and short-lasting psychedelic found in the venom of the Sonoran Desert toad. (Both compounds can also be synthesized in a laboratory.) Unfortunately. both of these compounds are illegal in the United States so the veterans must travel to Mexico for the actual treatments. In honor of Veteran's Day, the always-excellent Microdose republished Jan C. Hu's 2021 interview with Skiles:

What aspects of psychedelic therapy might help treat veterans in particular?

In treating PTSD, psychedelics enhance your ability to bring up trauma and simultaneously see it from different angles. Everything feels new, more revelatory and connected. There's the ability to take a step back and experience something in a totally new way.

One of the cooler things about psychedelic assisted therapies is you're not only getting those cognitive pieces, but you're also getting somatic, cathartic experiences at the same time. For people who've experienced sexual assault or combat exposure, you cut off a lot of sensation from your body and reconnecting to it is actually one of the main goals of all therapies. Having that experience along with these cognitive pieces is something that they call a codex condensed experience — it's happening in different constellations of the mind and body[…]

These therapies aren't legal in the U.S. What drove you and other vets to seek out these experiences in Mexico?

There's a bit of desperation; people have to leave the country to be able to get these therapies. These are folks who have spent careers in the U.S. Special Forces, with blast injuries or lesions on their brain. It's a group of folks who have tried every single therapy that's offered in the United States and have come up wanting more. They had to leave the country in order to have a therapeutic experience, and not be arrested for it.

It's important to give guys an ability to have the most up to date therapeutic access, but in the U.S.; it's also important for this to become regulated. We operate in the underground because that's the only place we can do this kind of thing.

Previously:
FDA denies approval of MDMA-assisted therapy for PTSD
These psychonauts are in training to take DMT trips that last hours or even days and report back… for science
'Please refrain from licking' toads, says National Park Service in unusual warning

Wednesday, November 06, 2024

 

Healing, spiritual purposes drive many veterans’ use of psychedelics



In survey, 85% of veterans report they benefited from the experience



Ohio State University





COLUMBUS, Ohio – Most U.S. military veterans who have used psychedelics reported in a recent study that they pursued the substances for healing or spiritual exploration, and over 80% said they benefited from the experience – even those who had challenging outcomes.

The survey also indicated many of the veterans would be more likely to seek mental health care, or return to care, at the U.S. Department of Veterans Affairs (VA) if psychedelic-assisted therapy were offered.

Findings from this comprehensive examination of veterans’ experiences with psychedelics can give clinicians a clearer understanding of the veteran community’s expectations and specific needs for mental health care, researchers say.

“Because of all of the complexity that veterans are experiencing and the higher risk they’re at for experiencing not just one, but several mental health and physical health-related challenges, it makes sense that they would be searching for opportunities to address those challenges, especially when they feel like they’re not being met with the current system here in the U.S.,” said lead author Alan Davis, associate professor and director of the Center for Psychedelic Drug Research and Education at The Ohio State University College of Social Work.

The study was published recently in the Journal of Psychoactive Drugs.

The VA estimates that more than 17 U.S. veterans die by suicide each day, according to 2021 data. And studies suggest between 44% and 72% of veterans are highly stressed during the transition from military to civilian life.

The research team, which included veterans, consulted with other past military service members to design a survey examining patterns of psychedelic use, perspectives of those who did and did not report use, and what kinds of benefits and adverse outcomes were associated with veterans’ use of the drugs. Veterans were referred to the survey through online advertisements and communities, email invitations and word of mouth.

“Understanding military veteran culture is crucial for civilian therapists working with this population,” said co-author Mark Bates, a retired U.S. Air Force pilot and clinical psychologist at Sunstone Therapies, a Maryland treatment center researching psychedelic-assisted therapies.

“It’s about avoiding inadvertently undermining the therapeutic relationship and knowing how to use military culture as an effective frame of reference. This is also part of the reason of why we carefully consulted with a team of veteran advisers in the development and validation of the survey questions.”

With veteran advocacy for access to psychedelic-assisted therapy increasing in recent years, Bates said, “There is a really pressing need to explore anything that’s promising for mental health treatment.”

The survey sample consisted of 426 participants categorized into two groups – those who had (217) and had not (209) used psychedelics. Drugs used by veterans included psilocybin (magic mushrooms), LSD, ketamine, MDMA (ecstasy), ayahuasca, ibogaine, 5-MeO-DMT (toad) and peyote/mescaline. The most commonly reported reasons for use were healing or treatment (69%), spiritual exploration (47.5%) or recreation (38.7%).

Compared to veterans who had not used psychedelics, the veterans who had taken the drugs were more likely to be older and had spent more time deployed during their service, and a larger proportion of them reported PTSD, depression and anxiety.

While some participants were alone when they used psychedelics, many reported taking them in spiritual locations or outdoors, with friends, or in medical clinics or retreat centers – both in the United States and abroad.

Overall, participants rated the psychedelic experiences as beneficial whether they considered the experience uniformly positive (88.6%) or endured one or more adverse outcomes (81.3%). The most common adverse outcomes were flashbacks and craving or trying to reduce use of psychedelics. Fewer participants reported being arrested or seeking medical treatment in relation to using the drugs.

Statistical analysis identified a number of factors that lowered the likelihood of having negative outcomes: being older, using psilocybin, having depression or anxiety, obtaining psychedelics from a safe source, being prepared, comfortable and confident during the treatment, and being able to trust, let go and be open to the experience.

“This finding highlights the importance of people in the veteran community knowing that keeping these things in mind prior to use can help set them up for the best possible outcome,” Davis said.

With most psychedelic substances classified as Schedule I drugs under the Controlled Substances Act, the only legal way for most people to access them in the United States currently is in a clinical trial setting. Davis is leading a current psilocybin-assisted therapy study at Ohio State for the treatment of PTSD among military veterans, and Bates and colleagues at Sunstone Therapies have treated many veterans to date.

Finding that surveyed veterans would welcome a chance to access psychedelic-assisted therapy at the VA is an important highlight of the study, the researchers said.

“What’s really exciting about this study and understanding veterans’ interest in psychedelic-assisted therapy is it’s potentially opening up an opportunity to address some of their core challenges head-on,” Davis said. “Veterans are dying by suicide and fleeing the country to find these opportunities in other places, so the message is clear. This needs to be available.”

Additional co-authors were Nathan Sepeda, Adam Levin and Stacey Armstrong of Ohio State; independent researcher Erik Lund; Robert Koffman of Sunstone Therapies; Katinka Hooyer of the Medical College of Wisconsin; and Rachel Yehuda of the Icahn School of Medicine at Mount Sinai.

This work was supported by private donors, the Cammack Family Gift Fund, the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn Medical School, the Johns Hopkins Center for Psychedelic and Consciousness Research, and the CPDRE at Ohio State.

#

Sunday, October 20, 2024

'Monkey on a Stick': From drug smuggling to murder, a gripping exposé of crime in the Hare Krishna movement


"It's about this human nature and our tendency to want leadership and to want to put our faith in authority figures," filmmaker Jason Lapeyre said

Elisabetta Bianchini
Updated Fri, October 18, 2024 


Adapted from the bestselling book co-authored by John Hubner and Lindsey Gruson, Canadian filmmaker Jason Lapeyre's documentary Monkey on a Stick looks at the criminal activity in the Hare Krishna movement, particularly in North America in the 1970s and 1980s. From drug smuggling to child sexual abuse and murder, the film dives into the shocking realities of the International Society for Krishna Consciousness (ISKCON).

Lapeyre initially read the novel in the early 2000s and it was immediately something he knew would be a great on-screen adaptation. Initially his idea was for the novel to inspire a dramatic feature and when he optioned the book in 2016, the intention transition to a series format. But ultimately a documentary materialized.

The film begins with the story of how Swami Prabhupada established this spiritual movement in New York City in 1965, quite quickly resulting in this "explosion" of devotees, with many attributing its success to the way Prabhupada was able to connect with individuals during the hippie era of culture.

Things got progressively worse in ISKCON after Prabhupada's death in 1977, when leadership was in the hands of 11 gurus from different temples.

"Instead of 11 bishops they got 11 popes trying to turn their temple into the Vatican," as it's described in the film.

At this point Lapeyre leads us through a variety of transgressions from these gurus, with titles like "The LSD Guru" and "The Rock 'n' Roll Guru," using dramatized sequences to depict what was happening. The brilliant setup of these sequences by Lapeyre will make you feel like you've stepped into a horror film.

Nori Muster in "Monkey on a Stick" (Sphere Media)

As Lapeyre stressed, the guiding light for this film is Nori Muster, who was a Los Angeles-based devotee in the '70s and '80s, who worked in the public relations department of ISKCON. She's also written her own book titled "Betrayal of the Spirit: My Life behind the Headlines of the Hare Krishna Movement."

"Nori, who is someone who was right at the heart of the story for the entire time period that we're talking about, she was someone who helped me put together the list of interview subjects. She was someone who did outreach with me," Lapeyre told Yahoo Canada. "She was literally sitting beside me when we interviewed people. She would sometimes take over the interview, I would invite her [to]."

"During the editing process I was sending cuts to Nori and asking for feedback. ... I had final cut of the film, but she was someone that I really wanted to feel ownership over the final product."

In terms of getting Muster's trust to be such an active participate in this film, Lapeyre really just established with her that they shared the same agenda.

"From the moment she left the movement, she's pretty ardently devoted her life to trying to get the story out," Lapeyre said. "At one point I said to her, 'Hey by the way, if you have any old footage, like VHS tapes or films of your time in ISKCON, that's something that might be great for the documentary.' And she was like, 'Oh, I'm so sorry, Jason, I don't have anything like that. All I have is hundreds of hours of recorded interviews with all the gurus and power players in the system.' My head exploded."

"Her journalistic impulses and her archival and historical impulses to keep all that stuff became really one of the key elements of the film. And this idea of history bearing witness and the testimony, the historical evidence of the criminal activity of the gurus in the organization, was something that we really wanted to literally show on camera. So once she understood that that's what we wanted to do, I think she was all in."

Monkey on a Stick (Dustin Rabin)
'It's a plea to interrogate that desire for leadership and authority'

There's a particularly interesting conversation that Muster has with Lapeyre at the end of the film where she says, "I was an adult. I let myself be brainwashed." But we hear Lapeyre pushback a bit on how much she's almost blaming herself for her involvement in the movement.

"I wanted to include that because I don't know what the right answer is," Lapeyre said. "You can hear me sort of arguing with her, but I watch that now and I'm like, 'Am I right, or is she right?'"

"I don't know that that's a question that has a great answer, and that's ultimately what I wanted to do with the film is maybe, hopefully, have people come out of the theatre talking about that. One of the things we say about the film a lot is that it's not about Krishna Consciousness, it's about this human nature and our tendency to want leadership and to want to put our faith in authority figures. But if the film is a plea for anything, it's a plea for critical thinking and it's a plea to interrogate that desire for leadership and authority."

Something that wasn't as fleshed out in the novel, but Lapeyre really wanted to bring forward in Monkey on a Stick, is the impact of early guidance in ISKCON that women had to be submissive to men. As Muster explains in the film, women were seen and temptations for men to "fall off the spiritual path." There was also a belief that women's brains and "smaller."

"If you had to point to one thing that caused almost everything else that happened, it's this decision at the very beginning of the movement that women are inferior to men," Lapeyre said. "In 2024, fortunately we've been educated a little bit, we have a little bit more of a sense that this is a power dynamic that can just easily cause abuse, and it's something that we're just starting ... to be able to recognize, but you maybe couldn't recognize in the late '70s and early 80s."

"When you make that decision that there's going to be a fundamental power dynamic based on gender in their organization, it's going to lead to almost every other abuse you see in the film. That was something that Nori recognized immediately and so hopefully it informs almost every one of the different abuses that we see in the film."

Monkey on a Stick (Dustin Rabin)

While it can be easy for viewers sitting at home to be judgemental about people not seeing the problematic signs in a movement like Hare Krishna and ISKCON, through a brilliant selection of participates who really open up about their experiences, whether born into the movement or people who are just deeply spiritual human beings, it's a comprehensive look at the need for critical thinking.

"I don't want people to go, 'Oh God what a freak show. What a bunch of idiots,'' Lapeyre said. "John has this amazing line in the film where he says people had invested so much of themselves into the idea that this was going to work, and I think this is a dynamic that I see myself, and I think it's something we see in online behaviour so much, which is really just behaviour now in 2024."

"I hope people come out of the film acknowledging that when you are that invested in an idea or a leader or a movement of any kind, whether it's artistic or bureaucratic or governmental or political, it is really, really hard to have that critical thinking moment of admitting that you were wrong."

Monkey on a Stick is now in select Toronto theatres, with release dates in additional markets to come

Saturday, October 12, 2024

Gazing at your dog can connect your brain with theirs, research shows

The Conversation
October 11, 2024 

French bulldog (Shutterstock)

It might sound far-fetched, but recent research suggests that dogs’ and humans’ brains synchronise when they look at each other.

This research, conducted by researchers in China, is the first time that “neural coupling” between different species has been witnessed.

Neural coupling is when the brain activity of two or more individuals aligns during an interaction. For humans, this is often in response to a conversation or story.

Neural coupling has been observed when members of the same species interact, including mice, bats, humans and other primates. This linking of brains is probably important in shaping responses during social encounters and might result in complex behaviour that would not be seen in isolation, such as enhancing teamwork or learning.

When social species interact, their brains “connect”. But this case of it happening between different species raises interesting considerations about the subtleties of the human-dog relationship and might help us understand each other a little better.

What’s new puppy dog?

The dog was one of the first animals humans domesticated. And they have a long history of sharing time and space with us. Dogs are not only companions for us, they also have key roles in our society, including therapeutic support, detecting diseases and protecting and herding livestock.

As a result, dogs have developed some impressive skills, including the ability to recognise and respond to our emotional state.

In the recent study, the researchers studied neural coupling using brain-activity recording equipment called non-invasive electroencephalography (EEG). This uses headgear containing electrodes that detect neural signals – in this case, from the beagles and humans involved in the study.




Looking into those irresistible eyes could help deepen your bond. Wirestock Creators/Shuterstock

Researchers examined what happened to these neural signals when dogs and people were isolated from each other, and in the presence of each other, but without looking at each other. Dogs and humans were then allowed to interact with each other.

Look into my eyes

When dogs and humans gazed at each other and the dogs were stroked, their brain signals synchronised. The brain patterns in key areas of the brain associated with attention, matched in both dog and person.

Dogs and people who became more familiar with each other over the five days of the study had increased synchronisation of neural signals. Previous studies of human-human interactions have found increased familiarity between people also resulted in more closely matching brain patterns. So the depth of relationship between people and dogs may make neural coupling stronger.


The ability of dogs to form strong attachments with people is well known. A 2022 study found the presence of familiar humans could reduce stress responses in young wolves, the dog’s close relative. Forming neural connections with people might be one of the ways by which the dog-human relationship develops.

The researchers also studied the potential effect of differences in the brain on neural coupling. They did this by including dogs with a mutation in a gene called Shank3, which can lead to impaired neural connectivity in brain areas linked with attention. This gene is responsible for making a protein that helps promote communication between cells, and is especially abundant in the brain. Mutations in Shank3 have also been associated with autism spectrum disorder in humans.

Study dogs with the Shank3 mutation did not show the same level of matching brain signals with people, as those without the mutation. This was potentially because of impaired neural signalling and processing.


However, when researchers gave the study dogs with the Shank3 mutation, a single dose of LSD (a hallucinogenic drug), they showed increased levels of attention and restored neural coupling with humans.

LSD is known to promote social behaviour in mice and humans, although clearly there are ethical concerns about such treatment.

The researchers were clear that there remains much to be learned about neural coupling between dogs and humans.


It might well be the case that looking into your dog’s eyes means that your respective brain signals will synchronise and enhance your connection. The more familiar you are with each other, the stronger it becomes, it seems.

So the next time a dog gazes at you with their puppy dog eyes, remember you could be enhancing your relationship.

Jacqueline Boyd, Senior Lecturer in Animal Science, Nottingham Trent University


This article is republished from The Conversation under a Creative Commons license. Read the original article.

Monday, September 16, 2024

 Research shows brain synchronization between humans and dogs

By 

Reviewed by Danielle Ellis, B.Sc.

Sep 16 2024

Study reveals how mutual gazing and petting synchronize human and dog brains, while autism-related gene mutations in dogs reduce this connection. 

Study: Disrupted Human–Dog Interbrain Neural Coupling in Autism-Associated Shank3 Mutant Dogs. Image Credit: sergey kolesnikov/Shutterstock.com
Study: Disrupted Human–Dog Interbrain Neural Coupling in Autism-Associated Shank3 Mutant Dogs. Image Credit: sergey kolesnikov/Shutterstock.com

In a recent study published in Advanced Science, researchers studied cross-species interbrain connections between dogs and humans. They also investigated whether autism-related gene abnormalities in dogs impede social interaction between human-dog pairs.

Background

The human-dog connection has developed with time, with dogs tamed for their protective and hunting capacities. They have become valuable members of households, offering companionship and emotional support. Interspecies partnerships generate mutual benefit but seldom approach the extent of communication between humans and dogs. Dogs can read, comprehend, and react to various human emotions and linguistic signs via facial expressions, behaviors, and voice tones. However, the brain mechanisms underlying interspecies social communication remain unknown.

About the study

In the present study, researchers investigated the brain processes enabling human-dog communication. They explored the influence of autism-related gene alterations in dogs on social interactions between the two species.

Non-invasive wireless electroencephalograms (EEG) concurrently detected brain activity in beagles (research canines) and humans during social interactions. To validate the findings, researchers assessed interbrain correlations between different areas of the brain under three situations. The situations included no social interactions in separate spaces, with social interaction in one room and without social engagement in one room. Social interactions included petting and mutual gazing.

Researchers compared interbrain coupling during complete social interactions (mutual gaze + petting) to partial social interactions (mutual gaze or petting alone) to evaluate the synergistic effects of mutual gaze and petting on interbrain coupling. They also investigated brain activity associations between dogs and human participants from different trials and recorded the brain activities of the two species during social interactions for five days to evaluate the impact of social familiarity on interbrain neural coupling.

Subsequently, researchers conducted an additional five-day investigation to assess the durability or changes in interbrain interactions across prolonged periods. Linear regressions investigated the association between the duration of social interactions and interbrain activity. Generalized partial directed coherence (GPDC) algorithms assessed the directionality of interbrain activity coupling.

Researchers developed an autism spectrum disorder (ASD) model for dogs with SH3 and multiple ankyrin repeat domain 3 (Shank3) mutations using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein 9 (Cas9) genome editing.

Behavioral studies such as the three-chamber test and human-dog interaction experiments revealed autism-like symptoms in the mutants. Over five days, researchers explored the interbrain neuronal connection between mutant canines and humans. Theta/beta wave ratios (TBR) indicated attention problems in the mutants during the social interactions between humans and dogs.

Researchers also explored the effects of lysergic acid diethylamide (LSD), a psychedelic, on brain function. They delivered a single dosage of 7.5 μg/kg bodyweight of LSD intramuscularly and observed its effects after 24 hours.

Results

Petting and mutual gazing resulted in interbrain synchronization in the parietal and frontal areas of the brain during human-dog interactions, respectively. These brain areas are involved in joint attention. The interbrain association in these brain areas of dogs and humans caused by mutual gazing or stroking alone was much lower than that during combined social interactions, including petting and mutual gazing.

Over five days, the synchronization intensity increased as the human-dog dyad became more familiar. Linear regression analyses revealed a strong positive association between social contact time, interbrain activity correlations, and GPDC values. After a week of social contacts, logistic growth curve regressions revealed that interbrain correlation in the frontal and parietal areas had plateaued. 

Interbrain correlations between humans and dogs in various sessions were much lower than in the same interaction sessions. The findings demonstrate that reciprocal involvement between dogs and humans is vital for interbrain neural connections. During the human-dog social interactions, the human takes the lead, and the dog follows. The mutant canines displayed lower attention and eliminated interbrain connections. A single dosage of LSD corrected the problems.

Conclusions

The study found that interbrain neural synchronizations between family dogs and human beings are identical to those observed during human-human interactions. The frontoparietal network is essential for interbrain activity coordination and sensory information attention. Dogs with Shank3 mutations demonstrated poor brain circuitry and attention, comparable to those with ASD. A single dosage of LSD restored reduced interbrain connection and joint attention in the mutant dogs, indicating that LSD may improve social impairment in ASD patients.

 The findings point to possible interbrain neural activity biological markers for autism spectrum disorder diagnosis and the development of designed non-hallucinogenic LSD analogs to address social deficiencies. Further research into brain coupling may improve the knowledge of the neurological mechanisms that underpin social interactions between regularly developing humans and those with mental illnesses like ASD.

Journal reference:

A Boy And His Dog (1975) Official Trailer

Thursday, September 12, 2024

Could America's divide on marijuana be coming to an end

The U.S. is divided when it comes to state and federal marijuana policy, but recent political developments could move the country toward greater acceptance of cannabis


By DAVID A. LIEB 
Associated Press
September 11, 2024

The U.S. is divided when it comes to state and federal marijuana policy, but recent political developments could move the country toward a greater acceptance of cannabis.

Both major presidential candidates have signaled support for a federal policy change to reclassify marijuana as a less dangerous drug, and voters in several additional states will get a say this fall on legalization.

Though still illegal under federal law, public approval of marijuana has grown significantly — and so has the number of states where it's legally sold in stores.

Possessing marijuana is a federal crime punishable by fines and prison time. Selling or cultivating marijuana is a more serious federal crime, punishable by prison sentences of five years to life, depending on the quantity of the drug.

But many states have abolished their own marijuana penalties.

Twenty-four states and the District of Columbia — representing 53% of the nation's population — have legalized marijuana and now tax and regulate sales similar to alcohol, according to the Marijuana Policy Project, which supports legalizing cannabis. An additional seven states have removed jail sentences for possessing small amounts of marijuana. A total of 38 states and the District of Columbia have laws that allow the medical use of marijuana.

The Justice Department in May proposed to reclassify marijuana from a Schedule I drug to a less dangerous Schedule III drug, which includes such things as ketamine and some anabolic steroids. But that switch involves a lengthy process.

The Drug Enforcement Administration has set a Dec. 2 hearing to take comment on the proposal. That means a final decision could come after President Joe Biden leaves office in January.

Vice President Kamala Harris, the Democratic nominee for president, backs marijuana decriminalization and has said it’s “absurd” that marijuana is classified as a Schedule I drug, alongside heroin and LSD.

Former President Donald Trump, the Republican presidential nominee, also signaled support for the policy change this past week. He posted on his social media platform that he would “continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug” and said he would vote “yes” on a Florida ballot proposal to legalize recreational marijuana.


The Florida initiative would allow recreational sales to people over 21 from existing medical marijuana dispensaries, with the potential for the Legislature to license additional retailers. The proposal needs at least a 60% vote to pass and would take effect six months after voter approval.

The campaign has been the costliest of nearly 160 measures on state ballots this year, attracting tens of millions of dollars of contributions primarily from supporters, according to the election tracking organization Ballotpedia. Among the opponents are the Florida Republican Party and Gov. Ron DeSantis, who has said it would reduce quality of life by leaving a marijuana stench in the air.

Voters in North and South Dakota will be asked for the third time whether to legalize marijuana beyond medical use. The measures need a simple majority to pass.

Nebraska Secretary of State Bob Evnen has said initiatives to legalize and regulate medical marijuana appear to have enough petition signatures to qualify for a statewide vote. He faces a Friday deadline to certify measures for the ballot.

About 70% of American adults said marijuana should be legal in a Gallup poll taken last year, the highest level recorded by the polling firm since it first asked about marijuana policy in 1969. By contrast, only about one-third of respondents supported marijuana legalization 20 years ago.

Last year's Gallup poll showed the highest support for marijuana among young voters, a key demographic in seven presidential battleground states.

An analysis of national survey data published earlier this year found that an estimated 17.7 million people reported using marijuana daily or near-daily in 2022 — up dramatically from less than 1 million people in 1992. Though alcohol is still more widely used, the report marked the first time that the number of Americans who use marijuana just about every day surpassed the number who drink that often.

As legal marijuana becomes more widespread, some state officials are battling the sale of unregulated products derived from hemp, which is federally classified as distinct from marijuana. Some of those products are sold in packaging similar to common candies or chips and contain delta-8 THC, a synthesized from of CBD that’s prevalent in hemp.

Some states have banned or restricted synthetic hemp products, including South Dakota and Wyoming, where new laws took effect July 1. Indiana authorities have warned stores to remove delta-8 THC products that they say also contain illegal amounts of the psychoactive delta-9 THC found in marijuana.

In Missouri, where marijuana was legalized in 2022, Republican Gov. Mike Parson raised concerns that certain hemp-derived products are being marketed to children and ordered a crackdown by the state health department. He joined with Attorney General Andrew Bailey on Tuesday to announce a task force focused on unregulated psychoactive cannabis products.

“We are not the only state facing this issue and not the only state taking action,” Parson said.




Wednesday, September 04, 2024


Psychedelics show promise for treating PTSD by suppressing learned fear responses



New research reveals how psychedelic drugs like psilocybin acutely reduce fear by altering activity in the amygdala, a key brain region involved in processing fear and anxiety




Genomic Press




MILWAUKEE, WI - Ongoing research is revealing how psychedelic drugs like psilocybin (the active ingredient in "magic mushrooms") and LSD may help treat post-traumatic stress disorder (PTSD) by suppressing learned fear responses. In a new Bench to Bedside peer-reviewed article published in the journal Psychedelics (ISSN: 2997-2671, Genomic Press, New York), researchers from the Medical College of Wisconsin provide an in-depth look at the neural mechanisms underlying psychedelics' acute fear-reducing effects in rodent models of PTSD.

The amygdala, an almond-shaped structure deep within the brain, plays a central role in fear learning and expression. Excitatory neurons in the lateral amygdala are activated by fearful stimuli, leading to a cascade of activity that drives fear responses. The new research proposes that psychedelic drugs suppress this fear-related activity by enhancing inhibitory signaling from GABAergic interneurons onto the excitatory neurons.

"Our hypothesis is that psychedelics acutely suppress learned fear responses by activating serotonin 2A receptors on inhibitory neurons in the amygdala," said the lead author Thomas Kelly, an MD/PhD candidate. "This leads to increased release of the inhibitory neurotransmitter GABA, which quiets the activity of excitatory neurons that normally drive fearful behaviors."

The finding that psychedelics' acute effects on fear require activation of serotonin 2A receptors aligns with the receptor's established role in the drugs' hallucinogenic effects. However, the authors emphasize the importance of considering the broader pharmacological profile and duration of action of different psychedelic compounds.

For example, the drug MDMA, which has shown promise for treating PTSD in late-stage clinical trials, does not directly activate serotonin 2A receptors. Instead, MDMA increases the release of serotonin, which then activates various serotonin receptor subtypes. The research suggests that psychedelics with faster onset and shorter duration of acute effects may be advantageous for PTSD treatment compared to longer-acting drugs like LSD.

"The insights from preclinical studies can help guide the design of clinical trials and treatment protocols that optimize the therapeutic potential of psychedelics for PTSD," said senior author Dr. Qing-song Liu. "By understanding the mechanisms and time-course of psychedelics' effects on fear circuitry, we can better harness these compounds in a clinical setting."

Several clinical trials are currently investigating psilocybin-assisted therapy for PTSD, with some protocols incorporating drug administration in combination with exposure therapy to promote fear extinction learning. As this research progresses, the amygdala is emerging as a key locus of interest for understanding how psychedelics may extinguish fearful memories and provide a novel treatment approach for PTSD and other fear-related disorders.

The full article, titled “Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation,” was published online on 09 August 2024 and is freely available online at the website of Psychedelics (Genomic Press, New York): https://pp.genomicpress.com/aop/

Contact: Thomas J. Kelly Medical College of Wisconsin tjkelly@mcw.edu 1-920-427-6177

Saturday, August 31, 2024

 DECRIMINALIZE DRUGS

Cannabis and hallucinogen use among adults remained at historic highs in 2023



Vaping among younger adults and binge drinking among mid-life adults also maintained historically high levels, NIH-supported study shows



NIH/National Institute on Drug Abuse




Past-year use of cannabis and hallucinogens stayed at historically high levels in 2023 among adults aged 19 to 30 and 35 to 50, according to the latest findings from the Monitoring the Future survey. In contrast, past-year use of cigarettes remained at historically low levels in both adult groups. Past-month and daily alcohol use continued a decade-long decline among those 19 to 30 years old, with binge drinking reaching all-time lows. However, among 35- to 50-year-olds, the prevalence of binge drinking in 2023 increased from five and 10 years ago. The Monitoring the Future study is conducted by scientists at the University of Michigan’s Institute for Social Research, Ann Arbor, and is funded by the National Institutes of Health.

Reports of vaping nicotine or vaping cannabis in the past year among adults 19 to 30 rose over five years, and both trends remained at record highs in 2023. Among adults 35 to 50, the prevalences of nicotine vaping and of cannabis vaping stayed steady from the year before, with long-term (five and 10 year) trends not yet observable in this age group as this question was added to the survey for this age group in 2019.

For the first time in 2023, 19- to 30-year-old female respondents reported a higher prevalence of past-year cannabis use than male respondents in the same age group, reflecting a reversal of the gap between sexes. Conversely, male respondents 35 to 50 years old maintained a higher prevalence of past-year cannabis use than female respondents of the same age group, consistent with what’s been observed for the past decade.

“We have seen that people at different stages of adulthood are trending toward use of drugs like cannabis and psychedelics and away from tobacco cigarettes,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “These findings underscore the urgent need for rigorous research on the potential risks and benefits of cannabis and hallucinogens – especially as new products continue to emerge.”

Since 1975, the Monitoring the Future study has annually surveyed substance use behaviors and attitudes among a nationally representative sample of teens. A longitudinal panel study component of Monitoring the Future conducts follow-up surveys on a subset of these participants (now totaling approximately 20,000 people per year), collecting data from individuals every other year from ages 19 to 30 and every five years after the participants turn 30 to track their drug use through adulthood. Participants self-report their drug use behaviors across various time periods, including lifetime, past year (12 months), past month (30 days), and other use frequencies depending on the substance type. Data for the 2023 panel study were collected via online and paper surveys from April 2023 through October 2023.

Full data summaries and data tables showing the trends below, including breakdowns by substance, are available in the report. Key findings include:

Cannabis use in the past year and past month remained at historically high levels for both adult age groups in 2023. Among adults 19 to 30 years old, approximately 42% reported cannabis use in the past year, 29% in the past month, and 10% daily use (use on 20 or more occasions in the past 30 days). Among adults 35 to 50, reports of use reached 29%, 19%, and 8%, respectively. While these 2023 estimates are not statistically different from those of 2022, they do reflect five- and 10-year increases for both age groups.

Cannabis vaping in the past year and past month was reported by 22% and 14% of adults 19 to 30, respectively, and by 9% and 6% of adults 35 to 50 in 2023. For the younger group, these numbers represent all-time study highs and an increase from five years ago.

Nicotine vaping among adults 19 to 30 maintained historic highs in 2023. Reports of past-year and past-month vaping of nicotine reached 25% and 19%, respectively. These percentages represent an increase from five years ago, but not from one year ago. For adults 35 to 50, the prevalence of vaping nicotine remained steady from the year before (2022), with 7% and 5% reporting past-year and past-month use.

Hallucinogen use in the past year continued a five-year steep incline for both adult groups, reaching 9% for adults 19 to 30 and 4% for adults 35 to 50 in 2023. Types of hallucinogens reported by participants included LSD, mescaline, peyote, shrooms or psilocybin, and PCP.

Alcohol remains the most used substance reported among adults in the study. Past-year alcohol use among adults 19 to 30 has showed a slight upward trend over the past five years, with 84% reporting use in 2023. However, past month drinking (65%), daily drinking (4%), and binge drinking (27%) all remained at study lows in 2023 among adults 19 to 30. These numbers have decreased from 10 years ago. Past-month drinking and binge drinking (having five or more drinks in a row in the past two week period) decreased significantly from the year before for this age group (down from 68% for past month and 31% for binge drinking reported in 2022).

Around 84% of adults 35 to 50 reported past-year alcohol use in 2023, which has not significantly changed from the year before or the past five or 10 years. Past-month alcohol use and binge drinking have slightly increased over the past 10 years for this age group; in 2023, past-month alcohol use was at 69% and binge drinking was at 27%. Daily drinking has decreased in this group over the past five years and was at its lowest level ever recorded in 2023 (8%).

Additional data: In 2023, past-month cigarette smoking, past-year nonmedical use of prescription drugs, and past-year use of opioid medications (surveyed as “narcotics other than heroin”) maintained five- and 10-year declines for both adult groups. Among adults 19 to 30 years old, past-year use of stimulants (surveyed as “amphetamines”) has decreased for the past decade, whereas for adults 35 to 50, past-year stimulant use has been modestly increasing over 10 years. Additional data include drug use reported by college/non-college young adults and among various demographic subgroups, including sex and gender and race and ethnicity.

The 2023 survey year was the first time a cohort from the Monitoring the Future study reached 65 years of age, therefore trends for the 55 to 65 year old age group are not yet available.

“The data from 2023 did not show us many significant changes from the year before, but the power of surveys such as Monitoring the Future is to see the ebb and flow of various substance use trends over the longer term,” said Megan Patrick, Ph.D., of the University of Michigan and principal investigator of the Monitoring the Future panel study. “As more and more of our original cohorts – first recruited as teens – now enter later adulthood, we will be able to examine the patterns and effects of drug use throughout the life course. In the coming years, this study will provide crucial data on substance use trends and health consequences among older populations, when people may be entering retirement and other new chapters of their lives.”

View more information on data collection methods for the Monitoring the Future panel study and how the survey adjusts for the effects of potential exclusions in the report. Results from the related 2023 Monitoring the Future study of substance use behaviors and related attitudes among teens in the United States were released in December 2023, and 2024 results are upcoming in December 2024.

If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.orgTo learn how to get support for mental health, drug or alcohol conditions visit FindSupport.govIf you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357).

###

About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

About substance use disorders: Substance use disorders are chronic, treatable conditions from which people can recover. In 2023, nearly 49 million people in the United States had at least one substance use disorder. Substance use disorders are defined in part by continued use of substances despite negative consequences. They are also relapsing conditions, in which periods of abstinence (not using substances) can be followed by a return to use. Stigma can make individuals with substance use disorders less likely to seek treatment. Using preferred language can help accurately report on substance use and addiction. View NIDA’s online guide.

NIH…Turn 

Plastic surgery patients who use marijuana also have elevated nicotine levels



Nicotine may be an unsuspected risk factor for complications, reports Plastic and Reconstructive Surgery®



Peer-Reviewed Publication

Wolters Kluwer Health




August 29, 2024 — Marijuana use is common among patients considering plastic surgery and is associated with elevated nicotine levels on laboratory tests, reports a paper in the September issue of Plastic and Reconstructive Surgery®the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer

"We found that patients who report marijuana use also have elevated urine nicotine and cotinine levels – even those who don't smoke or use other nicotine-containing products" comments ASPS Member Surgeon Joseph A. Ricci of Hofstra University School of Medicine, Great Neck, NY. "This raises concerns that unsuspected nicotine exposure might lead to an increased risk of postoperative complications." 

First study to assess marijuana and nicotine use in plastic surgery patients 

The rising prevalence of marijuana use raises questions about potential negative effects in patients undergoing surgery. Marijuana smoke contains carcinogens and irritants similar to those in tobacco smoke, with similarly harmful effects on pulmonary health. 

Nicotine causes impaired wound healing, which is a special concern in patients undergoing plastic surgery. The rising popularity of marijuana, combined with newer nicotine delivery products such as vapes, "presents a clinical challenge for healthcare providers to identify patients who are exposed to nicotine, as patients themselves may be unaware," the researchers write. 

Dr. Ricci and colleagues examined the possible link between marijuana use and nicotine exposure in 135 consecutive patients who consulted a surgeon to discuss cosmetic plastic surgery. Ninety-two percent of patients were women; the average age was 38 years. The patients were largely Hispanic, reflecting the demographics of the area served by the clinic. 

High nicotine levels raise 'concern for unrecognized surgical risk' 

In a survey, 19% of patients reported active nicotine use while 20% reported marijuana use: marijuana alone in 7% of patients and both nicotine and marijuana by 13%. Levels of nicotine and the nicotine metabolite cotinine were compared between groups. 

The results showed elevated nicotine and cotinine levels among patients who said they used marijuana. The association was apparent not only in those who reported nicotine-containing products, but also in those who denied any type of nicotine use. 

Although marijuana users had elevated nicotine, the levels weren't as high as typically found in patients who smoke or use other forms of nicotine. Most patients who reported marijuana and/or nicotine use on the study survey did not mention these substances during their discussion with the plastic surgeon. For this group, nicotine levels were comparable similar to those in active cigarette smokers. 

"Patients may be hesitant to disclose their substance use history, possibly due to a lack of awareness about the perioperative risks associated with smoking and marijuana use," the researchers write. In 84 patients who went on to have plastic surgery, nicotine levels were lower compared to patients who did not undergo surgery.  

Although the study did not find increased complication rates among marijuana users or those with elevated nicotine levels, the findings raise concern that such risks could occur. The researchers emphasize the need for definitive studies of the effects of marijuana on surgical outcomes. Meanwhile, Dr. Ricci and coauthors conclude: "In real clinical settings, under-reporting of nicotine-containing product use, including marijuana, remains a concern for unrecognized surgical risk and affects decision on offering elective procedures." 

Read Article: Patterns of Marijuana Use and Nicotine Exposure in Patients Seeking Elective Aesthetic Procedures 

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health

### 

About Wolters Kluwer 

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. 

Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.  

For more information, visit www.wolterskluwer.com, follow us on LinkedInFacebookYouTube and Instagram

29-Aug-2024ing Discovery Into Health®